| Company Name: | Ariad Pharmaceuticals | | Ticker Symbol: | ARIA | | | WWW Address: | www.ariad.com |
| CEO: | Dr. Harvey J. Berger,M.D. | | No. of Employees: | 300 |
| Common Issue Type: | CS | | Business Description: | Ariad Pharmaceuticals Inc is engaged in the discovery and development of breakthrough medicines to treat cancers by regulating cell signaling with small molecules.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
| | Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 18.24 |  -0.19 | 18.24 | 18.27 | 18.16 | 19.64 | 17.60 | 257549 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 3,368.8 | 184.7 | 1.24 | -1.34 | 0.00 | 0.0 | 0.0 | 25.40 - 15.13 |
| | KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 18.43 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 3,368.8 | mil |
| Latest Shares Outstanding | 184.7 | mil |
| Earnings pS (EPS) | -1.34 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | | % |
| Revenue per Employee | 1,860 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 178.8 | mil |
| Float as % of Shares Outstanding | 96.8 | % |
| Foreign Sales | | mil |
| Domestic Sales | | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 1,139.60 | % |
| Research & Devlopment (R&D) as % of Revenue | 2,264.80 | % |
| Gross Profit Margin | 96.1 | % |
| EBITDA Margin | 0.0 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | 0.0 | % |
| Return on Assets (ROA) | -50.8 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -58.7 | % |
| Current Ratio | 7.8 | |
| Leverage Ratio (Assets/Equity) | 1.2 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.08 | |
| LT Debt/Total Capital | 7.0 | % |
| Working Capital pS | 1.96 | $ |
| Cash pS | 2.02 | $ |
| Book-Value pS | 1.97 | $ |
| Tangible Book-Value pS | 1.97 | $ |
| Cash Flow pS | -1.20 | $ |
| Free Cash Flow pS | -1.06 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 9.35 | |
| Price/Tangible Book Ratio | 9.38 | |
| Price/Cash Flow | -15.4 | |
| Price/Free Cash Flow | -17.3 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | | | | | PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | 10.6 | 111 | 42,064 | 138,634 |
| 4 Weeks | 19.64 | 15.35 | 18.12 | 1.7 | 97 | 32,951 | 593,127 |
| 13 Weeks | 22.49 | 15.35 | 21.21 | -13.1 | 80 | 31,112 | 1,928,939 |
| 26 Weeks | 24.59 | 15.35 | 21.76 | -15.3 | 72 | 30,260 | 3,722,011 |
| 52 Weeks | 25.40 | 15.13 | 16.77 | 9.9 | 87 | 26,812 | 6,622,474 |
| YTD | 22.49 | 15.35 | - | -3.9 | 83 | 30,202 | 2,959,757 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 17.14 | 17.10 | 17.92 | 19.86 | 20.53 | 1.24 | 1.32 |
| | | | GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | -13.44 | 2.1 | -61.84 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 1.79 | NA | 12.09 |
| R&D | 25.20 | NA | 33.45 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | 7880.2 | 7880.2 | -97.8 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | -0.01 | -0.01 | -0.41 |
| | | | SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 66.31 |
| Current Ratio | 3.4 |
| Quick Ratio (Acid Test) | 3.4 |
| Liquidity Ratio (Cash) | 3.36 |
| Receivables Turnover | 8.3 |
| Average Collection Period | 43 |
| Working Capital/Equity | 105.9 |
| Working Capital pS | 0.72 |
| Cash-Flow pS | -1.27 |
| Free Cash-Flow pS | -0.95 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 25.21 |
| Financial Leverage Ratio (Assets/Equity) | 1.6 |
| Debt Ratio | 37.4 |
| Total Debt/Equity (Gearing Ratio) | 0.10 |
| LT Debt/Equity | 0.08 |
| LT Debt/Capital Invested | 15.2 |
| LT Debt/Total Liabilities | 13.5 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 0.15 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 4.52 |
| Tobin's Q Ratio | 18.89 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -16.13 |
| Enterprise Value (EV)/Free Cash Flow | -20.41 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 9.38 |
| Price/Book Ratio - LTM | 9.35 |
| Price/Cash Flow Ratio | -15.4 |
| Price/Free Cash Flow Ratio - LTM | -17.3 |
| Price/Sales Ratio | 490.40 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.05 |
| Current Liabilities pS | 0.29 |
| Tangible Book Value pS - LTM | 1.97 |
| Book Value pS - LTM | 1.97 |
| Capital Invested pS | 0.66 |
| Cash pS - LTM | 2.02 |
| Cash Flow pS - LTM | -1.20 |
| Free Cash Flow pS - LTM | -1.06 |
| Earnings pS (EPS) | -1.34 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -28,447.67 |
| Free Cash Flow Margin 5YEAR AVG | -6,024.44 |
| Net Profit Margin | 0.0 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | 0.00 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 0.00 |
| Return on Capital Invested (ROCI) | -181.1 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -146.9 |
| Assets Productivity | 0.00 |
| Return on Assets (ROA) | -122.6 |
| Return on Assets (ROA) - 5YEAR AVRG. | -54.4 |
| Gross Profit Margin | 96.1 |
| Gross Profit Margin - 5YEAR AVRG. | 0.0 |
| EBITDA Margin - LTM | 0.0 |
| EBIT Margin - LTM | 0.0 |
| Pre-Tax Profit Margin | 0.0 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | 0.0 |
| Effective Tax Rate - 5YEAR AVRG. | 0.0 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 65 |
| Revenue per Employee | 1,860 |
| Net Income per Employee | -736,240 |
| Average Collection Period | 65 |
| Receivables Turnover | 8.3 |
| Day's Inventory Turnover Ratio | |
| Inventory Turnover | 0.0 |
| Inventory/Sales | 0.0 |
| Accounts Payble/Sales | 1,481.54 |
| Assets/Revenue | 0.00 |
| Net Working Capital Turnover | 0.00 |
| Fixed Assets Turnover | 0.05 |
| Total Assets Turnover | 0.0 |
| Revenue per $ Cash | 0.00 |
| Revenue per $ Plant | 0.07 |
| Revenue per $ Common Equity | 0.00 |
| Revenue per $ Capital Invested | 0.00 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 10915.6 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 66.5 |
| Research & Devlopment (R&D) as % of Revenue | 25933.5 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 25933.5 |
|
|  
| | |  |  | |
| |
